No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes.

Fiche publication

Date publication

avril 2024

Journal

Diabetes & metabolism

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DUVILLARD Laurence , Pr PETIT Jean-Michel , Pr VERGES Bruno , Dr PAIS DE BARROS Jean-Paul

Tous les auteurs :
Duvillard L, de Barros JP, Rouland A, Simoneau I, Denimal D, Bouillet B, Petit JM, Vergès B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38653365

Résumé

The catabolism of high density lipoprotein (HDL) apolipoprotein AI (apoAI) is accelerated in patients with type 2 diabetes (T2D), related to hypertriglyceridemia, insulin resistance and low plasma adiponectin levels. Since liraglutide is likely to partly correct these abnormalities, we hypothesized that it might have a beneficial effect on HDL apoAI kinetics in patients with T2D.